TheraVasc

Parents

*Architects: Surgical & Diagnostic Technology _ Vascular, PAD (Peripheral Arterial Disease & CLI (Critical Limb Ischemia)
*Industry: Ohio
*WBT:Candidate Companies (2010)

Cleveland, Ohio
Dedicated to reducing the risk, cost and time associated with drug developement by focusing on developing repurposed drugs for u
In models of PAD, TV1001 selectively stimulates blood vessel formation in the affected limbs, reduces inflammation and has no significant side effects.
TheraVasc’s initial product, TV1001, targets patient populations with poor blood flow to the extremities, such as those with PAD or diabetic leg and foot problems.
TV1001 for treatment of Peripheral Artery Disease